Colin Hill

Colin Hill is a leading voice in AI and precision medicine. He is the co-founder of Aitia, formerly GNS Healthcare, where he serves as its Chief Executive Officer.

Hill serves on the board of Centrexion Therapeutics, a biotech company focused on developing and commercializing non-opioid, non-addictive chronic pain drugs. He previously served on the boards of Biotelemetry Inc., the leading mobile health information company, and PPD Inc., a leading global contract research organization. He was a founding member of the Board of Directors of AesRx, a biopharmaceutical company dedicated to the development of new treatments for sickle cell disease, and TMed (Transforming Medicine: The Elizabeth Kauffman Institute), a non-profit foundation dedicated to the advancement of personalized medicine.

Earlier in his career, Hill was appointed by the governor of Massachusetts to the state's Digital Health Council and was also named to MIT Technology Review’s TR100 list of the top 100 innovators in the world under the age of 35. Additionally, he was the founding chairman of O’Reilly Media’s Strata Rx, the first healthcare big data conference in the industry.

A frequent speaker at national and international scientific and industry conferences, Hill graduated from Virginia Tech with a degree in physics and earned Master’s degrees in physics from both McGill University and Cornell University.